Literature DB >> 29375140

The market for chimeric antigen receptor T cell therapies.

Amy Yip1, Rachel M Webster1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29375140     DOI： 10.1038/nrd.2017.266

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  28 in total

Review 1.  Synthetic Receptor-Based Targeting Strategies to Improve Tumor Drug Delivery.

Authors:  Susheel Kumar Nethi; Shubhmita Bhatnagar; Swayam Prabha
Journal:  AAPS PharmSciTech       Date:  2021-03-08       Impact factor: 3.246

Review 2.  Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Authors:  Ryan D Salinas; Joseph S Durgin; Donald M O'Rourke
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

3.  Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.

Authors:  Jing Cui; Qi Zhang; Qi Song; Herui Wang; Pauline Dmitriev; Mitchell Y Sun; Xiaoyu Cao; Yang Wang; Liemei Guo; Iris H Indig; Jared S Rosenblum; Chunxia Ji; Dongqing Cao; Kaiyong Yang; Mark R Gilbert; Yu Yao; Zhengping Zhuang
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 4.  Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells.

Authors:  Maysam Mansouri; Martin Fussenegger
Journal:  Protein Cell       Date:  2021-09-29       Impact factor: 15.328

5.  Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.

Authors:  Margaret M Billingsley; Nathan Singh; Pranali Ravikumar; Rui Zhang; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2020-02-05       Impact factor: 11.189

Review 6.  Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.

Authors:  Yamin Li; Zachary Glass; Mingqian Huang; Zheng-Yi Chen; Qiaobing Xu
Journal:  Biomaterials       Date:  2020-01-10       Impact factor: 12.479

7.  The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.

Authors:  Changwen Deng; Jingjing Zhao; Shixin Zhou; Jiebin Dong; Jixiang Cao; Junshuang Gao; Yun Bai; Hongkui Deng
Journal:  Mol Ther       Date:  2019-10-18       Impact factor: 11.454

Review 8.  Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.

Authors:  Mohamed Abou-El-Enein; Magdi Elsallab; Gerhard Bauer; Barbara Savoldo; Steven A Feldman; Andrew D Fesnak; Helen E Heslop; Peter Marks; Brian G Till
Journal:  Blood Cancer Discov       Date:  2021-08-03

9.  AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia.

Authors:  Waqas Nawaz; Bilian Huang; Shijie Xu; Yanlei Li; Linjing Zhu; Hu Yiqiao; Zhiwei Wu; Xilin Wu
Journal:  Blood Cancer J       Date:  2021-06-23       Impact factor: 11.037

10.  Single Molecule Force Spectroscopy Reveals Distinctions in Key Biophysical Parameters of αβ T-Cell Receptors Compared with Chimeric Antigen Receptors Directed at the Same Ligand.

Authors:  Debasis Banik; Maryam Hamidinia; Joanna Brzostek; Ling Wu; Hannah M Stephens; Paul A MacAry; Ellis L Reinherz; Nicholas R J Gascoigne; Matthew J Lang
Journal:  J Phys Chem Lett       Date:  2021-08-04       Impact factor: 6.888
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.